Dose-range Finding Efficacy and Safety Study for QBW251 in COPD Patients

• Sponsor: Novartis Pharmaceuticals (Industry)
• Overall Status: Completed
• CT.gov ID: NCT04072887
• Collaborator: (none)
• Enrollment: 974
• Locations: 148
• Arms: 6
• Actual Duration (Months): 28.7
• Patients Per Site: 6.6
• Patients Per Site Per Month: 0.2

Study Details

Study Description

Brief Summary

This clinical study was designed to support the dose selection for future studies by evaluating efficacy and safety of different QBW251 doses in Chronic obstructive pulmonary disease (COPD) patients with chronic bronchitis and a history of exacerbations, compared to placebo, when added to a triple inhaled therapy of LABA, LAMA and ICS.

Condition or Disease	Intervention/Treatment	Phase
Pulmonary Disease, Chronic Obstructive	Drug: QBW251; Drug: Placebo; Drug: COPD maintenance background therapy	Phase 2

Detailed Description

This study used a 6 treatment arm, parallel-group, randomized, double-blind study design. 974 male and female COPD patients were randomized into the trial. The study consisted of four distinct study periods:

• Screening (Weeks -3 to -2): Participants underwent a screening period of 1 week where were assessed for eligibility and tapered off disallowed medications.

• Run-in (Days -14 to 1): Subsequently, participants entered the run-in period of up to 2 weeks to establish baseline values for symptom assessments, to standardize the COPD background therapy (triple combination LABA/LAMA/ICS), and to complete eligibility assessments.

• Treatment (Day 1 to Week 24): Eligible participants moved into the Day 1 visit where they were stratified according to their smoking status (current or ex-smoker) and severity of airflow limitation (FEV1 ≥ 30% to < 50% and ≥ 50% to < 80%) and then randomized into 1 of 6 treatment arms with a randomization ratio of 2:2:1:1:1:2 (450 mg b.i.d., 300 mg b.i.d., 150 mg b.i.d., 75 mg b.i.d., 25 mg b.i.d., placebo). The treatment period consisted of 24 weeks, during which the participant returned to the site for regular visits (Day 1 - Week 24).

• Follow-up (Weeks 25-28): Upon completion of the treatment period, participants were followed up for safety assessments for 30 days.

Study Design

• Study Type: Interventional
• Actual Enrollment: 974 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: Triple (Participant, Care Provider, Investigator)
• Primary Purpose: Treatment
• Official Title: A 24-week Multi-center, Double-blind, Placebo Controlled Dose-range Finding Study to Investigate the Efficacy and Safety of Oral QBW251 in COPD Patients on Triple Inhaled Therapy (LABA / LAMA / ICS)
• Actual Study Start Date: Sep 12, 2019
• Actual Primary Completion Date: Oct 8, 2021
• Actual Study Completion Date: Feb 1, 2022

Arms and Interventions

Arm	Intervention/Treatment
Experimental: QBW251 450 mg QBW251 was orally administered 450 mg b.i.d for 24 weeks	Drug: QBW251; QBW251 oral capsules (450, 300, 150, 75 and 25 mg) of identical appearance to ensure blinding administered twice a day (b.i.d) for 24 weeks; Drug: COPD maintenance background therapy; Combination of fluticasone furoate, vilanterol and umeclidinium
Experimental: QBW251 300 mg QBW251 was orally administered 300 mg b.i.d for 24 weeks	Drug: QBW251; QBW251 oral capsules (450, 300, 150, 75 and 25 mg) of identical appearance to ensure blinding administered twice a day (b.i.d) for 24 weeks; Drug: COPD maintenance background therapy; Combination of fluticasone furoate, vilanterol and umeclidinium
Experimental: QBW251 150 mg QBW251 was orally administered 150 mg b.i.d for 24 weeks	Drug: QBW251; QBW251 oral capsules (450, 300, 150, 75 and 25 mg) of identical appearance to ensure blinding administered twice a day (b.i.d) for 24 weeks; Drug: COPD maintenance background therapy; Combination of fluticasone furoate, vilanterol and umeclidinium
Experimental: QBW251 75 mg QBW251 was orally administered 75 mg b.i.d for 24 weeks	Drug: QBW251; QBW251 oral capsules (450, 300, 150, 75 and 25 mg) of identical appearance to ensure blinding administered twice a day (b.i.d) for 24 weeks; Drug: COPD maintenance background therapy; Combination of fluticasone furoate, vilanterol and umeclidinium
Experimental: QBW251 25 mg QBW251 was orally administered 25 mg b.i.d for 24 weeks	Drug: QBW251; QBW251 oral capsules (450, 300, 150, 75 and 25 mg) of identical appearance to ensure blinding administered twice a day (b.i.d) for 24 weeks; Drug: COPD maintenance background therapy; Combination of fluticasone furoate, vilanterol and umeclidinium
Placebo Comparator: Placebo Placebo was orally administered b.i.d for 24 weeks	Drug: Placebo; Placebo oral capsules administered twice a day for 24 weeks; Drug: COPD maintenance background therapy; Combination of fluticasone furoate, vilanterol and umeclidinium

Outcome Measures

Primary Outcome Measures

1. Change From Baseline in Forced Expiratory Volume in One Second (FEV1) at week 12 [Baseline and Week 12]

   The primary efficacy analysis assessed the effect of QBW251 on the absolute change from baseline in trough FEV1 in liters on Week 12. Forced Expiratory Volume in one second (FEV1) is calculated as the volume of air forcibly exhaled in one second as measured by a spirometer. Baseline measurement was defined as the baseline visit pre-bronchodilator spirometry assessment. A positive trend for change from baseline in FEV1 across the dose range is considered a favorable outcome. Change from baseline in the FEV1 mean scores were analyzed using a Mixed Model for Repeated Measures (MMRM): treatment + baseline score + smoking status at screening + run-in FEV1 + airflow limitation severity + region + time interval + treatment*time interval interaction + baseline score*time interval interaction.

Secondary Outcome Measures

1. Change From Baseline in Forced Expiratory Volume in One Second (FEV1) [Baseline, weeks 4, 8, 16, 20 and 24]

   The primary efficacy analysis assessed the effect of QBW251 on the absolute change from baseline in trough FEV1 in liters compared to placebo on Weeks 4, 8, 16, 20 and 24. Forced Expiratory Volume in one second (FEV1) is calculated as the volume of air forcibly exhaled in one second as measured by a spirometer. Baseline measurement was defined as the baseline visit pre-bronchodilator spirometry assessment. A positive trend for change from baseline in FEV1 across the dose range is considered a favorable outcome. Change from baseline in the FEV1 mean scores were analyzed using a Mixed Model for Repeated Measures (MMRM): treatment + baseline score + smoking status at screening + run-in FEV1 + airflow limitation severity + region + time interval + treatment*time interval interaction + baseline score*time interval interaction.

2. Change from baseline in Evaluating Respiratory Symptoms (E-RS); Total score [Baseline, weeks 12 and 24]

   The E-RS assesses overall daily respiratory COPD symptoms (Total score) and it is derived as the sum of 11 severity items; a higher scores indicate more severe symptoms. Change from baseline in the E-RS Total weekly mean scores were analyzed using a Mixed Model for Repeated Measures (MMRM): treatment + baseline score + smoking status at screening + run-in E-RS + airflow limitation severity + region + time interval + treatment*time interval interaction + baseline score*time interval interaction. The mean baseline E-RS Total score was the average of the corresponding daily scores from the run-in period. Lower scores in the change from baseline correspond to lower symptom severity.

3. Change from baseline in Evaluating Respiratory Symptoms (E-RS); Cough and Sputum score [Baseline, weeks 12 and 24]

   The E-RS assesses both overall daily respiratory COPD symptoms (Total score) and specific respiratory symptoms using 3 subscales (Breathlessness, Cough & Sputum, and Chest Symptoms). The E-RS comprises 11 severity items and higher scores indicate more severe symptoms. The Cough and Sputum subscale score was derived as the sum of items 2 - 4. Change from baseline in the E-RS Cough and Sputum weekly mean scores were analyzed using a Mixed Model for Repeated Measures (MMRM): treatment + baseline score + smoking status at screening + run-in E-RS + airflow limitation severity + region + time interval + treatment*time interval interaction + baseline score*time interval interaction. The mean baseline E-RS Cough & Sputum subscale score was the average of the corresponding daily scores from the run-in period. Lower scores in the change from baseline correspond to lower symptom severity.

4. Number of Participants with a "Better" change in the Patient Global Impression of Severity (PGI-S) from baseline [Baseline, weeks 12 and 24]

   The PGI-S questionnaire is a patient-reported outcomes score that rates the severity of the respiratory symptoms and of cough and mucus. The change in severity scores (Better, No change and Worse) from baseline were reported at weeks 12 and 24. Thus, the number of participants with a Better change in the severity score are reported in the table below.

5. Change from baseline in the Cough and Sputum Assessment Questionnaire (CASA-Q) [Baseline, weeks 12 and 24]

   The CASA-Q is a validated questionnaire instrument used to measure cough and sputum production, and their impact in patients COPD and/or chronic bronchitis. It contains a total of 20 items on a 5-step scale distributed in 4 domains: Cough symptoms, Cough impact, Sputum symptoms and Sputum impact. All items are rescored from 1-5 to 0-4 and then reverse scored such that better responses have higher scores. The four domains are ranged from 0-100 where higher scores associated with fewer symptoms/less impact due to cough or sputum. Within each domain, items are summed and rescaled: CASA-Q domain scores= (sum of rescored items) / (range of rescored items) ×100 Change from baseline in the CASA-Q cough and symptoms scores were analyzed using a Mixed Model for Repeated Measures (MMRM): treatment + baseline score + smoking status at screening + run-in E-RS + airflow limitation severity + region + time interval + treatment*time interval interaction + baseline score*time interval interaction.

6. Change from baseline in St. George's Respiratory Questionnaire (SGRQ) [Baseline, weeks 12 and 24]

   SGRQ measures health impairment and contains 50 items divided into three components: Symptoms, Activity and Impacts. A score was calculated for each component and a "Total" score was also calculated. In each case the lowest possible value is zero and the highest 100. Higher values correspond to greater impairment of quality of life. Change from baseline in the SGRQ scores were analyzed using a Mixed Model for Repeated Measures (MMRM): treatment + baseline score + smoking status at screening + baseline SGRQ score + airflow limitation severity + region + time interval + treatment*time interval interaction + baseline score*time interval interaction.

7. Minimum plasma concentration (Cmin) for QBW251 [Days 15, 29, 57, 85, 113, 141 and 169]

   Venous whole blood samples were collected for pharmacokinetics characterization. Cmin was calculated from plasma concentration data using non-compartmental methods and summarized using descriptive statistics. Cmin was measured pre dose at all visits. All concentration below the lower limit of quantification (LLOQ) was treated as zero.

8. Maximum plasma concentration (Cmax) for QBW251 [Days 1, 15 and 169]

   Venous whole blood samples were collected for pharmacokinetics characterization. Cmax was calculated from plasma concentration data using non-compartmental methods and summarized using descriptive statistics. Cmax was estimated using the 3hr concentration for participants not in the Serial PK set. For participants in the Serial PK set, the calculated Cmax is presented only for Day 1 and Day 15. All concentration below the lower limit of quantification (LLOQ) was treated as zero.

9. Maximum plasma concentration (Cmax) for QBW251 in Serial PK set [Days 1 and 15]

   Venous whole blood samples were collected for pharmacokinetics characterization. Cmax was calculated from plasma concentration data using non-compartmental methods and summarized using descriptive statistics. All concentration below the lower limit of quantification (LLOQ) was treated as zero.

10. Area under de curve from time 0 to 24 hours (AUC0-24h) of QBW251 in Serial PK set [Days 1 and 15]

    Venous whole blood samples were collected for pharmacokinetics characterization. AUC0-24h was calculated from plasma concentration-time data using non-compartmental methods and summarized using descriptive statistics. AUC0-24h was estimated as 2 x AUC0-12h. All concentration below the lower limit of quantification (LLOQ) was treated as zero.

Eligibility Criteria

Criteria

• Ages Eligible for Study: 40 Years and Older
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion Criteria:

• Male and female COPD patients aged ≥40 years, who have signed an Informed Consent Form prior to initiation of any study-related procedure.

• Current or ex-smokers who have a smoking history of at least 10 pack years.

• Patients who have been treated with a triple combination of LABA/LAMA/ICS for the last 3 months prior to screening.

• Patients featuring chronic bronchitis

Exclusion Criteria:

• Patients who have had a COPD exacerbation that required treatment with antibiotics and/or oral corticosteroids and/or hospitalization, or a respiratory tract infection in the 4 weeks prior to screening, or between screening and randomization.

• Patients with any documented history of asthma, or with an onset of chronic respiratory symptoms, including a COPD diagnosis, prior to age 40 years.

• Patients with a body mass index (BMI) of more than 40 kg/m2.

• Use of other investigational drugs (approved or unapproved) within 30 days or 5 half-lives prior to screening, or until the expected pharmacodynamic effect has returned to baseline (e.g., biologics), whichever is longer; or longer if required by local regulations.

• Pregnant or nursing (lactating) women, and women of childbearing potential not willing to use acceptable effective methods of contraception during study participation.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Novartis Investigative Site	Andalusia	Alabama	United States	36420
2	Novartis Investigative Site	Los Angeles	California	United States	90025
3	Novartis Investigative Site	Westminster	California	United States	92683
4	Novartis Investigative Site	Ormond Beach	Florida	United States	32174
5	Novartis Investigative Site	Sarasota	Florida	United States	34233
6	Novartis Investigative Site	Winter Park	Florida	United States	32789
7	Novartis Investigative Site	Florence	Kentucky	United States	41042
8	Novartis Investigative Site	Crowley	Louisiana	United States	70526
9	Novartis Investigative Site	New Orleans	Louisiana	United States	70115
10	Novartis Investigative Site	Zachary	Louisiana	United States	70791
11	Novartis Investigative Site	Livonia	Michigan	United States	48152
12	Novartis Investigative Site	Edina	Minnesota	United States	55435
13	Novartis Investigative Site	Minneapolis	Minnesota	United States	55407
14	Novartis Investigative Site	Saint Charles	Missouri	United States	63301
15	Novartis Investigative Site	Saint Louis	Missouri	United States	63141
16	Novartis Investigative Site	Omaha	Nebraska	United States	68134
17	Novartis Investigative Site	Charlotte	North Carolina	United States	28207
18	Novartis Investigative Site	Gastonia	North Carolina	United States	28054
19	Novartis Investigative Site	Shelby	North Carolina	United States	28150
20	Novartis Investigative Site	Columbus	Ohio	United States	43215
21	Novartis Investigative Site	Medford	Oregon	United States	97504
22	Novartis Investigative Site	El Paso	Texas	United States	79903
23	Novartis Investigative Site	Houston	Texas	United States	77030
24	Novartis Investigative Site	McKinney	Texas	United States	75069
25	Novartis Investigative Site	Midlothian	Virginia	United States	23114
26	Novartis Investigative Site	Berazategui	Buenos Aires	Argentina	1888
27	Novartis Investigative Site	Mar del Plata	Buenos Aires	Argentina	7600
28	Novartis Investigative Site	Concepcion del Uruguay	Entre Ríos	Argentina	3260
29	Novartis Investigative Site	Rosario	Santa Fe	Argentina	S2000AII
30	Novartis Investigative Site	Rosario	Santa Fe	Argentina	S2000DBS
31	Novartis Investigative Site	Ciudad Autonoma de Bs As		Argentina	C1425FVH
32	Novartis Investigative Site	Mendoza		Argentina	5500
33	Novartis Investigative Site	Mendoza		Argentina	M5500CBA
34	Novartis Investigative Site	Salta		Argentina	4000
35	Novartis Investigative Site	Santa Fe		Argentina	S3000FIL
36	Novartis Investigative Site	South Brisbane	Queensland	Australia	4101
37	Novartis Investigative Site	Clayton	Victoria	Australia	3168
38	Novartis Investigative Site	Footscray	Victoria	Australia	3011
39	Novartis Investigative Site	Spearwood	Western Australia	Australia	6163
40	Novartis Investigative Site	Feldbach		Austria	8330
41	Novartis Investigative Site	Grieskirchen		Austria	4710
42	Novartis Investigative Site	Thalheim bei Wels		Austria	4600
43	Novartis Investigative Site	Erpent		Belgium	5100
44	Novartis Investigative Site	Leuven		Belgium	3000
45	Novartis Investigative Site	Liege		Belgium	4000
46	Novartis Investigative Site	Sherwood Park	Alberta	Canada	T8H 0N2
47	Novartis Investigative Site	Sainte Foy	Quebec	Canada	G1V 4G5
48	Novartis Investigative Site	St-Charles-Borromee	Quebec	Canada	J6E 2B4
49	Novartis Investigative Site	Zipaquira	Cundinamarca	Colombia	250252
50	Novartis Investigative Site	Liberec	Czech Republic	Czechia	460 05
51	Novartis Investigative Site	Ostrava Poruba	Czech Republic	Czechia	708 68
52	Novartis Investigative Site	Teplice	Czech Republic	Czechia	415 01
53	Novartis Investigative Site	Varnsdorf		Czechia	40747
54	Novartis Investigative Site	Aalborg		Denmark	DK 9000
55	Novartis Investigative Site	Copenhagen		Denmark	DK-2400
56	Novartis Investigative Site	Hvidovre		Denmark	2650
57	Novartis Investigative Site	Montpellier cedex 5	Herault	France	34059
58	Novartis Investigative Site	Lyon Cedex 04		France	69317
59	Novartis Investigative Site	Pessac Cedex		France	33604
60	Novartis Investigative Site	Reims		France	51092
61	Novartis Investigative Site	Berlin		Germany	10119
62	Novartis Investigative Site	Berlin		Germany	12157
63	Novartis Investigative Site	Berlin		Germany	12159
64	Novartis Investigative Site	Frankfurt		Germany	60596
65	Novartis Investigative Site	Halle		Germany	06108
66	Novartis Investigative Site	Hamburg		Germany	20354
67	Novartis Investigative Site	Landsberg		Germany	86899
68	Novartis Investigative Site	Leipzig		Germany	04207
69	Novartis Investigative Site	Leipzig		Germany	D-04299
70	Novartis Investigative Site	Leipzig		Germany	D-04347
71	Novartis Investigative Site	Mainz		Germany	55131
72	Novartis Investigative Site	Marburg		Germany	35037
73	Novartis Investigative Site	Mittweida		Germany	09648
74	Novartis Investigative Site	Witten		Germany	58452
75	Novartis Investigative Site	Thessaloniki	GR	Greece	570 10
76	Novartis Investigative Site	Heraklion Crete		Greece	711 10
77	Novartis Investigative Site	Guatemala City	GTM	Guatemala	01010
78	Novartis Investigative Site	Guatemala City	GTM	Guatemala	01011
79	Novartis Investigative Site	Guatemala City		Guatemala	01011
80	Novartis Investigative Site	New Territories		Hong Kong
81	Novartis Investigative Site	Pokfulam		Hong Kong
82	Novartis Investigative Site	Budapest		Hungary	1106
83	Novartis Investigative Site	Godollo		Hungary	2100
84	Novartis Investigative Site	Komarom		Hungary	2900
85	Novartis Investigative Site	Mako		Hungary	6900
86	Novartis Investigative Site	Pecs		Hungary	7635
87	Novartis Investigative Site	Genova	GE	Italy	16132
88	Novartis Investigative Site	Siena	SI	Italy	53100
89	Novartis Investigative Site	Negrar	VR	Italy	37024
90	Novartis Investigative Site	Nagoya	Aichi	Japan	457 8510
91	Novartis Investigative Site	Nagoya	Aichi	Japan	457-8511
92	Novartis Investigative Site	Fukuoka city	Fukuoka	Japan	811-1394
93	Novartis Investigative Site	Fukuoka-city	Fukuoka	Japan	819-8555
94	Novartis Investigative Site	Kasuga-city	Fukuoka	Japan	816-0813
95	Novartis Investigative Site	Koga city	Fukuoka	Japan	811 3195
96	Novartis Investigative Site	Yanagawa-city	Fukuoka	Japan	832-0059
97	Novartis Investigative Site	Mizunami-city	Gifu	Japan	509 6134
98	Novartis Investigative Site	Asahikawa-city	Hokkaido	Japan	070-8644
99	Novartis Investigative Site	Sapporo	Hokkaido	Japan	062-8618
100	Novartis Investigative Site	Naka-gun	Ibaraki	Japan	319-1113
101	Novartis Investigative Site	Kawasaki-city	Kanagawa	Japan	210-0852
102	Novartis Investigative Site	Sagamihara-city	Kanagawa	Japan	252-0392
103	Novartis Investigative Site	Yokohama-city	Kanagawa	Japan	223-0059
104	Novartis Investigative Site	Matsusaka-city	Mie	Japan	515-8544
105	Novartis Investigative Site	Sendai-shi	Miyagi	Japan	983 8520
106	Novartis Investigative Site	Kawachinagano	Osaka	Japan	586-8521
107	Novartis Investigative Site	Kishiwada-city	Osaka	Japan	596-8501
108	Novartis Investigative Site	Toyonaka	Osaka	Japan	560-8552
109	Novartis Investigative Site	Chuo ku	Tokyo	Japan	104-0031
110	Novartis Investigative Site	Chuo-ku	Tokyo	Japan	103-0003
111	Novartis Investigative Site	Chuo-ku	Tokyo	Japan	103-0028
112	Novartis Investigative Site	Kodaira	Tokyo	Japan	187-0024
113	Novartis Investigative Site	Setagaya-Ku	Tokyo	Japan	157-0072
114	Novartis Investigative Site	Setagaya-ku	Tokyo	Japan	158-8531
115	Novartis Investigative Site	Shinagawa	Tokyo	Japan	140-8522
116	Novartis Investigative Site	Toshima ku	Tokyo	Japan	170 0003
117	Novartis Investigative Site	Yamagata city	Yamagata	Japan	990-8533
118	Novartis Investigative Site	Osaka		Japan	531-0073
119	Novartis Investigative Site	Seoul	Seocho Gu	Korea, Republic of	06591
120	Novartis Investigative Site	Daegu		Korea, Republic of	705703
121	Novartis Investigative Site	Incheon		Korea, Republic of	21431
122	Novartis Investigative Site	Eindhoven		Netherlands	5623 EJ
123	Novartis Investigative Site	Harderwijk		Netherlands	3840 AC
124	Novartis Investigative Site	Lipa City	Batangas	Philippines	4217
125	Novartis Investigative Site	Iloilo city	Iloilo	Philippines	5000
126	Novartis Investigative Site	Bulacan		Philippines	3020
127	Novartis Investigative Site	Iloilo City		Philippines	5000
128	Novartis Investigative Site	Manila		Philippines	1000
129	Novartis Investigative Site	Grudziadz		Poland	86-300
130	Novartis Investigative Site	Katowice		Poland	40-648
131	Novartis Investigative Site	Zawadzkie		Poland	47-120
132	Novartis Investigative Site	Bardejov	Slovak Republic	Slovakia	085 01
133	Novartis Investigative Site	Bojnice	Slovak Republic	Slovakia	972 01
134	Novartis Investigative Site	Humenne	Slovak Republic	Slovakia	066 01
135	Novartis Investigative Site	Poprad		Slovakia	058 01
136	Novartis Investigative Site	Presov		Slovakia	080 01
137	Novartis Investigative Site	Spisska Nova Ves		Slovakia	052 01
138	Novartis Investigative Site	Vysne Hagy		Slovakia	5984
139	Novartis Investigative Site	Marbella	Andalucia	Spain	29603
140	Novartis Investigative Site	Alzira	Comunidad Valenciana	Spain	46600
141	Novartis Investigative Site	Girona		Spain	17005
142	Novartis Investigative Site	Songkhla	Hat Yai	Thailand	90110
143	Novartis Investigative Site	Khon Kaen	THA	Thailand	40002
144	Novartis Investigative Site	Bangkok		Thailand	10330
145	Novartis Investigative Site	Bangkok		Thailand	10400
146	Novartis Investigative Site	Adana		Turkey	01330
147	Novartis Investigative Site	Mersin		Turkey	33079
148	Novartis Investigative Site	London		United Kingdom	EC1A 7BE

Sponsors and Collaborators

• Novartis Pharmaceuticals

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: Novartis Pharmaceuticals
• ClinicalTrials.gov Identifier: NCT04072887
• Other Study ID Numbers: CQBW251B2201; 2018-003197-28
• First Posted: Aug 28, 2019
• Last Update Posted: Jul 29, 2022
• Last Verified: Jul 1, 2022

• Individual Participant Data (IPD) Sharing Statement: Yes
• Plan to Share IPD: Yes
• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No
• Keywords provided by Novartis Pharmaceuticals: COPD
• Additional relevant MeSH terms: Pulmonary Disease, Chronic Obstructive

Study Results

No Results Posted as of Jul 29, 2022